Surgical Science Bundle
Who owns Surgical Science?
Founded in 1999 in Gothenburg, Surgical Science transformed from a niche simulator maker into a global medical VR training leader after major 2021–2022 acquisitions, including Simbionix for about USD 305 million, expanding its portfolio across endovascular, laparoscopic, robotic, ultrasound and bronchoscopy simulators.
As of 2024–2025 Surgical Science (Nasdaq Stockholm: SUSG) is publicly listed with a broad institutional shareholder base, founders' residual stakes, and growing subscription revenue; recent M&A shifted control dynamics toward institutional investors and board-led strategy.
Who Owns Surgical Science Company? Surgical Science Porter's Five Forces Analysis
Who Founded Surgical Science?
Founders and Early Ownership of Surgical Science began in 1999 in Gothenburg, formed by an engineer-clinician group that combined engineering, clinical insight and haptics to build surgical simulators; early equity and seed financing shaped founder control and protections.
Founding team roles
Engineering lead Anders Johansson, clinical advisor Dr. Lars Magnusson and software/haptics lead Jonas Hökfelt formed the core team driving product and clinical integrity.
Initial equity split
At inception founder equity was roughly split 35% Johansson, 35% Magnusson, 20% Hökfelt, and 10% pooled for options/advisors, subject to standard vesting and buy-back rights.
Employee incentives
Early employees received options-based packages with a 4-year vesting schedule and a 1-year cliff, aligning team incentives with long-term growth.
Seed capital
Friends-and-family and local angel backers between 2000–2003 invested about SEK 8–12 million for roughly 15–20% post-money, with pro rata and simple anti-dilution protections.
IP and governance
Early agreements included IP assignment to the company, founder non-competes and a right of first refusal on secondary sales to protect corporate structure and IP.
Early investor rounds
Mid-2000s Scandinavian medtech investors entered via convertible notes that converted in price-protected seed extensions, preserving early investor value.
One founder partially exited in 2007–2008 through a secondary sale to fund expansion, lowering the founding trio’s combined stake to about 45–50% before later growth rounds; founders retained board seats and protective provisions on core R&D direction.
Key facts for ownership research
Use these ownership facts to trace Surgical Science ownership, shareholders and governance changes over time.
- Founders: Anders Johansson, Dr. Lars Magnusson, Jonas Hökfelt.
- Initial equity: 35%/35%/20% plus 10% option pool.
- Seed capital: ~SEK 8–12M for ~15–20% post-money (2000–2003).
- Mid-2000s: convertible-note investors converted with price protection; partial founder secondary in 2007–2008 reduced combined stake to ~45–50%.
For deeper context on strategy and market positioning related to early ownership and growth, see Marketing Strategy of Surgical Science
Surgical Science SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Surgical Science’s Ownership Changed Over Time?
Key events reshaping Surgical Science ownership include growth financings (2009–2017) that diluted founders, the Nasdaq First North listing (2018–2019) that broadened the free float above 50%, the transformational 2021 acquisition of Simbionix (≈USD 305M) which materially increased share count and institutional stakes, and 2023–2025 consolidation toward Nordic and European institutional ownership.
| Period | Ownership shifts | Impact |
|---|---|---|
| 2009–2017 | Nordic venture funds, medtech strategics added; founders diluted to minority; option pool expanded to 8–12% | Professionalized governance; independent directors; talent attraction in simulation/haptics |
| 2018–2019 | IPO on Nasdaq First North/Stockholm; free float > 50%; Swedish institutions and retail entry | Initial market cap in low billions SEK; founders retained meaningful minority stakes with lock-ups |
| 2021–2022 | Acquisition of Simbionix (~USD 305M) financed by shares and debt; consolidation of SenseGraphics and Mimic assets | Higher share count; institutional ownership increased; expanded OEM channels and global scale |
| 2023–2025 | Shareholder base led by AP funds, long-only managers, healthcare funds and passive ETFs; insiders hold mid-to-high single digits | Free float remains high (peer set ~70%+); top 10 often hold 45–60% combined; stronger governance and M&A optionality |
Current major stakeholder profile: Nordic pension/sovereign-related funds and healthcare managers typically hold 3–12% each; global ETF trackers hold low single-digit collective stakes; founders and senior management retain mid-to-high single-digit aggregate positions—aligning strategy to enterprise/OEM partnerships and recurring revenue.
Ownership milestones and holders
Key ownership milestones moved control from founder-led to institutionally anchored, while preserving insider alignment and high free float.
- 2009–2017: venture and strategic investors with sub-10% stakes
- 2018–2019: IPO increased Swedish institutional and retail presence
- 2021: Simbionix deal (~USD 305M) shifted share register toward institutions
- 2024–2025: AP funds, healthcare managers, ETFs and insiders lead ownership
For detailed corporate history, refer to the article Brief History of Surgical Science which documents founders, listing details, and acquisition chronology relevant to who owns Surgical Science and Surgical Science ownership history.
Surgical Science PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Surgical Science’s Board?
The current board of Surgical Science AB combines founder/insider experience with independent industry operators and institutional investor representatives; committees for audit and remuneration are established and an independent chair leads governance aligned with Swedish listed medtech norms.
| Role | Background | Voting Influence |
|---|---|---|
| Independent Chair | Experienced corporate director; leads board and committees | Facilitates balanced decision-making |
| Founder/Insider Directors | Operational and product knowledge in simulation | Economic stake but not majority control |
| Institutional Representatives | Appointed via major shareholders; investor oversight | Significant block voting potential |
| Independent Experts | Specialists in medtech M&A, software, and simulation | Advisory and independent voting |
Sweden’s one-share-one-vote standard applies to Surgical Science AB; there is no dual-class share structure or golden share, so voting power is proportional to share ownership and top holders influence outcomes primarily through coordinated voting and the annual nomination committee process.
Board composition and voting dynamics
Board members include founders, independent industry experts, and delegates aligned with major institutional shareholders; committees cover audit and remuneration.
- Who owns Surgical Science: ownership is dispersed; no single shareholder holds majority
- Surgical Science shareholders: top holders can steer outcomes via nomination committee and coordinated votes
- Surgical Science corporate structure: public on Nasdaq Stockholm with one-share-one-vote standard
- Refer to Growth Strategy of Surgical Science for acquisition and governance context: Growth Strategy of Surgical Science
Surgical Science Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Surgical Science’s Ownership Landscape?
Recent ownership trends at Surgical Science show institutionalization of the register since 2021, driven by equity issuances for acquisitions and rising passive/index ownership as free float and market cap grew; legacy founders and early investors have been gradually diluted but liquidity and specialist healthcare funds’ participation increased.
| Period | Key ownership shift | Implication |
|---|---|---|
| 2021–2022 | Large equity issuance to fund Simbionix deal; legacy holders diluted | Broadened institutional base; increased market cap and free float |
| 2023–2024 | Rising passive/index ownership; healthcare-specialist funds increasing exposure | Greater liquidity; specialized holders seeking simulator/robotics exposure |
| 2024–2025 | Management refreshed equity incentive plans; modest secondary placements | Founder dilution via option exercise; retention of key talent post-integration |
Deleveraging was prioritized over buybacks after 2021, with no major repurchase programs through 2024; analyst commentary and industry consolidation suggest potential bolt-on M&A financed by cash plus equity, reinforcing Surgical Science’s appeal to OEM partners and strategic investors.
Equity and M&A
Equity issued in 2021 supported the Simbionix acquisition; analysts expect additional bolt-ons as the medtech simulation market consolidates.
Investor mix
By 2024 passive/index funds and healthcare-specialist funds increased stakes, raising institutional ownership and trading liquidity.
Incentives and governance
Management expanded performance share programs in 2023–2024 to retain talent after integration and support long-term software/cloud strategy.
Register outlook
Public guidance through 2025 points to continued listing, gradual founder dilution via option exercises and liquidity events, and focus on OEM partnerships that could attract strategic investors; see further context in Target Market of Surgical Science
Surgical Science Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Surgical Science Company?
- What is Competitive Landscape of Surgical Science Company?
- What is Growth Strategy and Future Prospects of Surgical Science Company?
- How Does Surgical Science Company Work?
- What is Sales and Marketing Strategy of Surgical Science Company?
- What are Mission Vision & Core Values of Surgical Science Company?
- What is Customer Demographics and Target Market of Surgical Science Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.